A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 19, 2013

Primary Completion Date

September 4, 2015

Study Completion Date

July 19, 2017

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab

Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.

Trial Locations (23)

1000

CHU St Pierre (St Pierre), Brussels

2300

AZ Turnhout Sint Elisabeth, Turnhout

2820

Imeldaziekenhuis, Bonheiden

4000

Clinique Saint-Joseph, Liège

5000

CHR de Namur, Namur

7000

CHU Ambroise Paré, Mons

7100

CH Jolimont - Lobbes (Jolimont), Haine-Saint-Paul

8000

AZ Sint Jan, Bruges

8400

AZ Damiaan, Ostend

9000

AZ Maria Middelares, Ghent

AZ Sint Lucas (Sint Lucas), Ghent

UZ Gent, Ghent

9300

Onze Lieve Vrouwziekenhuis Aalst, Aalst

2210001

Western Galilee Hospital; Oncology-Nahariya, Nahariya

3109601

Rambam Medical Center; Oncology, Haifa

4428164

Meir Medical Center; Oncology, Kfar Saba

4941492

Rabin MC; Davidof Center - Oncology Institute, Petah Tikva

5262000

Chaim Sheba medical center, Oncology division, Ramat Gan

6093000

Assaf Harofeh; Oncology, Ẕerifin

6423906

Sourasky / Ichilov Hospital; Dept. of Oncology, Tel Aviv

7610001

Kaplan Medical Center; Oncology Inst., Rehovot

8410100

Soroka Medical Center; Oncology Dept, Beersheba

9112000

Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01926886 - A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC) | Biotech Hunter | Biotech Hunter